Use of Zoledronic Acid in Breast Cancer
Conditions
Keywords
Breast cancer
Brief summary
The investigators will involve about 25 Patients of postmenopausal women who have ER/PR positive early breast cancer in each arm. The study is a two-arm comparative, prospective, interventional, and randomized study. All patients who are on oral daily letrozole (2.5 mg), will be randomly assigned to receive either immediate or delayed ZOL (4 mg via 15-min infusion every 6 months) for 24 months. Immediate-ZOL patients will receive ZOL immediately after randomization; delayed-ZOL patients will receive ZOL only if their T-score fall below -2.0, after a nontraumatic clinical fracture, or if an asymptomatic fracture will be detected by spinal X-ray at the 3- monthly assessment. All patients will receive daily supplements containing calcium (500 mg) and vitamin D (400-800 IU). Baseline bone mineral density and every 3 months will be done for the enrolled patients.
Detailed description
The investigators will involve about 25 Patients of postmenopausal women who have ER/PR positive early breast cancer in each arm. The study is a two-arm comparative, prospective, interventional, and randomized study. All patients who are on oral daily letrozole (2.5 mg), will be randomly assigned to receive either immediate or delayed ZOL (4 mg via 15-min infusion every 6 months) for 24 months. Immediate-ZOL patients will receive ZOL immediately after randomization; delayed-ZOL patients will receive ZOL only if their T-score fall below -2.0, after a nontraumatic clinical fracture, or if an asymptomatic fracture will be detected by spinal X-ray at the 3- monthly assessment. All patients will receive daily supplements containing calcium (500 mg) and vitamin D (400-800 IU). Baseline bone mineral density and every 3 months will be done for the enrolled patients. -Research outcome measures: 1. Primary (main): The primary endpoint will be the percentage change in lumber spine (L2-L4) BMD at 12 months for immediate- versus delayed-ZOL patients. 2. Secondary (subsidiary): Secondary end points will include percentage change in total hip BMD at each assessment, fracture incidence, time to disease recurrence (local relapse or distant metastasis), DFS, and safety.
Interventions
(4 mg via 15-min infusion every 6 months) for 24 months
Sponsors
Assiut University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
45 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Histologic evidence of ER/PR positive breast adenocarcinoma 2. Postmenopausal women. 3. Baseline LS and total hip BMD T-score \> -2.0. 4. No prior treatment with denosumab or IV bisphosphonates is allowed. 5. No prior treatment with radiopharmaceuticals. 6. Not pregnant and not nursing. 7. Good dental health. 8. ECOG performance status 0-2. 9. Calculated creatinine clearance \>= 30 mL/min. 10. Corrected serum calcium \>= 8.0 mg/dL (2.00 mmol/L) and \< 11.6 mg/dL (2.90 mmol/L)
Exclusion criteria
1. Patients with dental problems. 2. Patients with impaired renal functions 3. Patients with osteopenia, or T- score is below -2.0 4. Patients with history of serious drug hypersensitivity or drug allergy.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The percentage change in lumber spine (L2-L4) BMD at 12 and 24 months for immediate- versus delayed-ZOL patients. | 24 months | The percentage change in lumber spine (L2-L4) BMD at 12 and 24 months for immediate- versus delayed-ZOL patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| percentage change in total hip BMD at each assessment, fracture incidence in percentage, time to disease recurrence in months (local relapse or distant metastasis), DFS in months, and safety. | 24 months | percentage change in total hip BMD at each assessment, fracture incidence in percentage, time to disease recurrence in months (local relapse or distant metastasis), DFS in months, and safety. |
| Fracture incidence in percentage | 24 months | Assessment of incidence fracture in the participants |
Countries
Egypt
Contacts
Primary ContactMai Abdelgelil, Assistant Lecturer Of Clinical
Outcome results
None listed